Healthcare & Pharma
M&A Database
In the Healthcare & Pharma sector, the average EBITDA multiple recorded since the beginning of the year is 12.8x, which represents a stable level compared to 2025. Sign up for free to unlock financial data on each deal including Enterprise Value and transaction multiples (xRevenue, xEBITDA, xEBIT).
Market Valuation Trends in Healthcare & Pharma
Average xEBITDA
Database
230 Deals Indexed in Healthcare & Pharma
Deals
| Date | Target | Acquirer | Sector | Rev | EV | xEBITDA |
|---|---|---|---|---|---|---|
| 04/2026 | CÉFIMÉCA FRANCE | OURY MEDICAL | Medical Devices | XX.X | XXX | X.Xx |
| 03/2026 | GLEAMER FRANCE | RADNET | Health Tech | XX.X | XXX | X.Xx |
| 03/2026 | LONZA CHI Switzerland | LONE STAR FUNDS | Pharma & Biotech | XX.X | XXX | X.Xx |
| 03/2026 | HIPP TECHNOLOGY GROUP GERMANY | DEUTSCHE BETEILIGUNGS (DBAG) | Medical Devices | XX.X | XXX | X.Xx |
| 03/2026 | WINNCARE FRANCE | SIPAREX | Medical Devices | XX.X | XXX | X.Xx |
| 02/2026 | DAREN TECHNOLOGY CHINA | CIMG | Pharma & Biotech | XX.X | XXX | X.Xx |
| 02/2026 | DUTSCHER FRANCE | VIVO CAPITAL | Medical Devices | XX.X | XXX | X.Xx |
| 02/2026 | HEALTH IN CODE (HIC) SPAIN | MERIEUX EQUITY PARTNERS | Healthcare Facilities | XX.X | XXX | X.Xx |
| 02/2026 | HALLMARQ VETERINARY IMAGING UNITED KINGDOM | NORD HOLDING | Medical Devices | XX.X | XXX | X.Xx |
| 02/2026 | PROSYS IRELAND | IMA GROUP | Medical Devices | XX.X | XXX | X.Xx |
| 01/2026 | QUIPMENT FRANCE | SAGARD | Healthcare Services | XX.X | XXX | X.Xx |
| 01/2026 | CLINIQUE DE LA VISION (REFRACT SAS) FRANCE | POINT VISION | Outpatient Care | XX.X | XXX | X.Xx |
| 01/2026 | OPTUM UK UNITED KINGDOM | TPG | Health Tech | XX.X | XXX | X.Xx |
| 01/2026 | CARNE GROUP IRELAND | PERMIRA | Healthcare Services | XX.X | XXX | X.Xx |
| 01/2026 | VILLARD FRANCE | YOTTA CAPITAL | Medical Devices | XX.X | XXX | X.Xx |
What does the Healthcare & Pharma M&A sector cover?
On mynth, the Healthcare & Pharma M&A sector is structured across 3 major verticals with Life Sciences, Health Providers, and Healthcare Services, covering 11 sub-sectors and 16 granular industry tags. This taxonomy mirrors how M&A professionals actually segment the market, enabling precise peer group construction and sector-specific EV/EBITDA benchmarking across European Small & Mid-Cap transactions.
What is the average EV/EBITDA multiple for Healthcare & Pharma transactions in 2026?
mynth tracks 230+ verified Healthcare & Pharma M&A transactions with an average EV/EBITDA of 12.8x for the year 2026. Our Healthcare & Pharma vertical provides deep granular data across the entire value chain of the Healthcare & Pharma industries. We track valuation multiples and transaction financials for a wide range of sub-industries, including Life Sciences, Animal Health, Medical Devices, Implants & Prosthetics, Diagnostic Equipment, Medical Consumables, Pharma & Biotech, CDMO, Generics / Labs and R&D Biotech. Whether you are looking for benchmarks in niche Healthcare & Pharma segments or broad market trends, mynth centralizes deal flow intelligence that covers specialized mid-market players and large-scale industrial consolidators across Europe. Our database is specifically designed to help analysts identify EBITDA multiples and Revenue trends within these highly regulated and capital-intensive sectors.
Who are the most active acquirers in European Healthcare & Pharma M&A?
According to mynth's community-contributed database of European Healthcare & Pharma transactions over the last 5 years, 72.8% of deals were driven by Private Equity firms while 27.2% were led by strategic acquirers. Among the most active buyers tracked on mynth: Ardian, a private equity firm based in France, with 17 transactions, Eqt Partners, a private equity firm based in Sweden, with 9 deals, Permira, a private equity firm based in United Kingdom, with 9 operations, Eurazeo, a private equity firm based in France, with 5 acquisitions, Ik Partners, a private equity firm based in United Kingdom, with 5 transactions. This breakdown reflects the consolidation dynamics of the European Healthcare & Pharma mid-market, where Private Equity firms have been particularly active in consolidating outpatient care, dental networks and veterinary clinics through buy-and-build strategies, while strategic acquirers focus on pharma and medtech bolt-on acquisitions.
What is mynth?
mynth is the first free M&A database dedicated to European Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.
How to use mynth for free?
Sign up for free and instantly receive 30 credits. Through our referral program, each person you invite earns you an additional 20 credits, meaning you can unlock at least 50 financial data points without spending a cent. Our search engine is built for speed and precision: filter transactions by company name, investment fund, sector, country, revenue range, enterprise value or date. A list system lets you group transactions into custom peer groups and export them directly to Excel. The credit model means you only spend on the deals you actually need : no subscription, no commitment.
Powered by Collective Intelligence
mynth is a community-driven database. Every transaction is contributed by M&A and Private Equity professionals who work on the deals themselves. This means our database contains off-market financial data that you will not find in any press release, news article, or traditional data provider. Closed deals, undisclosed valuations, real EBITDA multiples : data that only exists within the deal teams. Every single financial figure submitted is reviewed and validated by our in-house analysts before being published, ensuring the data you see is accurate, structured, and reliable.